SCHEMBL3003784

SCHEMBL3003784

O=S(=O)(c1c(F)c(F)c(F)c(F)c1F)N1CCN(c2nc(Cc3ccc(F)c(Cl)c3)cs2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPK1 P28482 3/20 0.37
MAPT P10636 4/20 0.36
KMT2A Q03164 4/20 0.36
LMNA P02545 4/20 0.36
MEN1 O00255 3/20 0.36
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GAA P10253 1/20 0.35
PKM P14618 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
AR P10275 2/20 0.34
RAB9A P51151 1/20 0.34
POLB P06746 1/20 0.34
LPAR1 Q92633 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651870 0.94 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3017854 0.93 L3MBTL1 (0.41) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3009090 0.92 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3002027 0.92 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3020835 0.91 PKM (0.45) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3013754 0.91 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3018157 0.89 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3011284 0.89 SMN1; SMN2 (0.40) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3002094 0.89 MEN1 (0.41) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3006920 0.89 LMNA (0.42) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.